10:55 AM EST, 11/03/2025 (MT Newswires) -- QuidelOrtho ( QDEL ) said Monday the US Food and Drug Administration cleared its VITROS hs Troponin I Assay to support in diagnosis of myocardial infarction.
The company said the test measures cardiac troponin I levels in human plasma using its VITROS Systems, which employ dry-slide and MicroWell technologies.
QuidelOrtho ( QDEL ) added that the commercial launch for US labs using VITROS platforms is set for later in the year.
Price: 26.66, Change: -0.33, Percent Change: -1.22